Acamprosate and Disulfiram Interaction
Drug interaction information between Acamprosate and Disulfiram.
Acamprosate and Disulfiram have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Acamprosate and Disulfiram. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Disulfiram does not change the way your body breaks down or uses acamprosate.
What To Do
No special changes are usually needed when taking these two drugs at the same time.
FDA Label Information
The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology (12.3) ].
Disulfiram Also Interacts With
- Phenytoin moderate
- Amitriptyline minor
- Metronidazole minor
- Nabilone minor
- Naltrexone minor
Frequently Asked Questions
Can I take Acamprosate and Disulfiram together?
This is a minor interaction. No special changes are usually needed when taking these two drugs at the same time.
How serious is the interaction between Acamprosate and Disulfiram?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Acamprosate and Disulfiram interact?
Disulfiram does not change the way your body breaks down or uses acamprosate.
Understanding the Acamprosate and Disulfiram Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Acamprosate belongs to the GABA Analog (Alcohol Dependence) class and Disulfiram belongs to the Aldehyde Dehydrogenase Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Disulfiram does not change the way your body breaks down or uses acamprosate. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Acamprosate has 3 total documented interactions on file in this dataset, and Disulfiram has 8. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: No special changes are usually needed when taking these two drugs at the same time. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Acamprosate or Disulfiram based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.